NASDAQ:COCP Cocrystal Pharma (COCP) Stock Price, News & Analysis $1.46 +0.05 (+3.28%) As of 03:59 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock About Cocrystal Pharma Stock (NASDAQ:COCP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Cocrystal Pharma alerts:Sign Up Key Stats Today's Range$1.36▼$1.4850-Day Range$1.17▼$1.9652-Week Range$1.12▼$3.26Volume33,952 shsAverage Volume29,355 shsMarket Capitalization$14.85 millionP/E RatioN/ADividend YieldN/APrice Target$7.00Consensus RatingBuy Company OverviewCocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.Read More… Cocrystal Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks39th Percentile Overall ScoreCOCP MarketRank™: Cocrystal Pharma scored higher than 39% of companies evaluated by MarketBeat, and ranked 524th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingCocrystal Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageCocrystal Pharma has received no research coverage in the past 90 days.Read more about Cocrystal Pharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Cocrystal Pharma are expected to decrease in the coming year, from ($1.85) to ($2.16) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cocrystal Pharma is -0.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cocrystal Pharma is -0.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCocrystal Pharma has a P/B Ratio of 0.58. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Cocrystal Pharma's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.02% of the float of Cocrystal Pharma has been sold short.Short Interest Ratio / Days to CoverCocrystal Pharma has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCocrystal Pharma does not currently pay a dividend.Dividend GrowthCocrystal Pharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.02% of the float of Cocrystal Pharma has been sold short.Short Interest Ratio / Days to CoverCocrystal Pharma has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Cocrystal Pharma this week, compared to 0 articles on an average week.Search Interest1 people have searched for COCP on MarketBeat in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cocrystal Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders25.64% of the stock of Cocrystal Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 6.72% of the stock of Cocrystal Pharma is held by institutions.Read more about Cocrystal Pharma's insider trading history. Receive COCP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cocrystal Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address COCP Stock News HeadlinesCocrystal Pharma's Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 VariantsApril 24 at 8:00 AM | globenewswire.comCocrystal Pharma Presents to Investment CommunityApril 23 at 6:10 PM | tipranks.comNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. April 24, 2025 | Porter & Company (Ad)Cocrystal Pharma to Present at Life Science Innovation Northwest 2025 ConferenceApril 16, 2025 | globenewswire.comOTC Markets Hosts Virtual Investor Presentation with Dr. Sam Lee, Co-CEO & President, and Jim Martin, Co-CEO & CFO, of Cocrystal Pharma, with David Bautz, PhD, Senior Analyst ...April 10, 2025 | msn.comCocrystal Pharma Approves 2025 Equity Incentive PlanApril 8, 2025 | tipranks.comCOCP: Norovirus Challenge Study Planned for 2025…April 2, 2025 | finance.yahoo.comCocrystal Pharma Reports 2024 Financial Results and Provides Updates on its Antiviral Drug-Development ProgramsMarch 31, 2025 | globenewswire.comSee More Headlines COCP Stock Analysis - Frequently Asked Questions How have COCP shares performed this year? Cocrystal Pharma's stock was trading at $2.02 at the start of the year. Since then, COCP shares have decreased by 26.2% and is now trading at $1.49. View the best growth stocks for 2025 here. How were Cocrystal Pharma's earnings last quarter? Cocrystal Pharma, Inc. (NASDAQ:COCP) issued its quarterly earnings data on Thursday, March, 27th. The company reported ($0.32) EPS for the quarter, beating analysts' consensus estimates of ($0.55) by $0.23. When did Cocrystal Pharma's stock split? Shares of Cocrystal Pharma reverse split on Tuesday, October 11th 2022. The 1-12 reverse split was announced on Tuesday, October 11th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 11th 2022. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. How do I buy shares of Cocrystal Pharma? Shares of COCP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cocrystal Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cocrystal Pharma investors own include NVIDIA (NVDA), Meta Platforms (META), OPKO Health (OPK), Advanced Micro Devices (AMD), NIO (NIO), CrowdStrike (CRWD) and Pfizer (PFE). Company Calendar Last Earnings3/27/2025Today4/24/2025Next Earnings (Estimated)5/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:COCP CIK1412486 Webwww.cocrystalpharma.com Phone(305) 425-1780FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Stock Price Target$7.00 High Stock Price Target$7.00 Low Stock Price Target$7.00 Potential Upside/Downside+369.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-17,980,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-94.62% Return on Assets-78.24% Debt Debt-to-Equity RatioN/A Current Ratio7.32 Quick Ratio7.32 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.59 per share Price / Book0.58Miscellaneous Outstanding Shares10,170,000Free Float7,565,000Market Cap$15.15 million OptionableNot Optionable Beta2.21 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:COCP) was last updated on 4/24/2025 by MarketBeat.com Staff From Our PartnersJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredTrump’s treachery Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...Porter & Company | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredThe Collapse Is Already HereWhen a system is about to fail, those trained to spot it often notice before anyone else. Tim Plaehn flew high...Investors Alley | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | Sponsored‘Wheels Are Falling Off’ the U.S. Stock MarketThe last time the U.S. economy looked like this, stocks didn't move for 16 years... And many investors lost...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cocrystal Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cocrystal Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.